Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
60760-0636-20 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 26, 2018 In Use
60760-0636-30 60760-0636 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 15, 2019 In Use
60760-0637-10 60760-0637 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
60760-0637-15 60760-0637 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 3, 2020 In Use
60760-0637-20 60760-0637 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 13, 2018 Dec. 31, 2021 In Use
60760-0637-30 60760-0637 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 10, 2019 In Use
60760-0654-10 60760-0654 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 22, 2022 In Use
60760-0715-12 60760-0715 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 6, 2021 In Use
60760-0715-21 60760-0715 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 25, 2020 In Use
60760-0790-12 60760-0790 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 20, 2022 In Use
60760-0790-21 60760-0790 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 20, 2022 In Use
60760-0932-21 60760-0932 Prednisone PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 9, 2021 In Use
60763-0376-06 60763-0376 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral April 10, 2017 In Use
60763-0601-13 60763-0601 Mercaptopurine PURINETHOL 50.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral Jan. 15, 2022 In Use
61126-0003-10 61126-0003 Cisplatin Platinol 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 Jan. 13, 2012 In Use
61126-0004-01 61126-0004 Cisplatin Platinol-AQ 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 In Use
61126-0004-02 61126-0004 Cisplatin Platinol-AQ 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 Jan. 13, 2012 In Use
61269-0750-10 61269-0750 Tretinoin Vesanoid 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Feb. 1, 2024 In Use
61269-0850-10 61269-0850 Tretinoin TRETINOIN 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Feb. 1, 2024 In Use
61314-0304-01 61314-0304 filgrastim-sndz Zarxio 300.0 ug/.5mL, 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0304-10 61314-0304 filgrastim-sndz Zarxio 300.0 ug/.5mL, 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0312-01 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0312-10 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0866-01 61314-0866 pegfilgrastim-bmez ZIEXTENZO 6.0 mg/.6mL Ancillary Therapy Immunostimulant Colony-Stimulating Factor Subcutaneous Nov. 4, 2019 In Use
61570-0072-01 61570-0072 Esterified Estrogens Menest 0.3 mg/1 Hormonal Therapy Estrogen Oral Sept. 28, 1977 In Use
61570-0073-01 61570-0073 Esterified Estrogens Menest 0.625 mg/1 Hormonal Therapy Estrogen Oral Sept. 28, 1977 In Use
61570-0074-01 61570-0074 Esterified Estrogens Menest 1.25 mg/1 Hormonal Therapy Estrogen Oral Sept. 28, 1977 In Use
61570-0075-50 61570-0075 Esterified Estrogens, Estrogens, Esterified Menest 2.5 mg/1 Hormonal Therapy Estrogen Oral Sept. 17, 2018 In Use
61570-0180-01 61570-0180 Estradiol Valerate Delestrogen Hormonal Therapy Estrogen July 15, 1954 Oct. 1, 2007 No Longer Used
61570-0181-01 61570-0181 Estradiol Valerate Delestrogen Hormonal Therapy Estrogen July 15, 1954 Oct. 1, 2007 No Longer Used
61570-0182-01 61570-0182 Estradiol Valerate Delestrogen Hormonal Therapy Estrogen July 15, 1954 Oct. 1, 2007 No Longer Used
61699-0047-02 61699-0047 Methylprednisolone Sodium Succinate Solu-Medrol 125.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous July 18, 2014 In Use
61703-0124-40 61703-0124 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Jan. 9, 2023 In Use
61703-0150-05 61703-0150 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0262-05 61703-0262 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0303-46 61703-0303 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 31, 1990 In Use
61703-0304-36 61703-0304 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 28, 1994 In Use
61703-0305-38 61703-0305 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 4, 1990 In Use
61703-0309-06 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-16 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-25 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 27, 2013 In Use
61703-0309-26 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 19, 2014 In Use
61703-0319-22 61703-0319 Cytarabine Cytarabine 100.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Nov. 22, 1999 In Use
61703-0323-22 61703-0323 Bleomycin Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 10, 2000 In Use
61703-0324-18 61703-0324 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous Oct. 1, 2005 In Use
61703-0325-18 61703-0325 Pamidronate Disodium Pamidronate Disodium 6.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous July 28, 2003 In Use
61703-0326-18 61703-0326 Pamidronate Disodium Pamidronate Disodium 9.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous Oct. 1, 2005 In Use
61703-0327-22 61703-0327 Dacarbazine Dacarbazine 10.0 mg/mL Chemotherapy Alkylating Agent Purine Analog Intravenous Oct. 18, 2001 May 31, 2019 No Longer Used
61703-0332-18 61703-0332 Bleomycin Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 11, 2000 In Use
61703-0339-18 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-22 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-50 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-56 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 23, 2004 In Use
61703-0341-06 61703-0341 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous April 9, 2007 Oct. 31, 2017 No Longer Used
61703-0341-09 61703-0341 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous April 2, 2007 May 31, 2019 No Longer Used
61703-0342-09 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-22 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-50 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0343-18 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-65 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-66 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0344-18 61703-0344 Fludarabine Phosphate Fludarabine Phosphate 50.0 mg/2mL Chemotherapy Antimetabolite Purine Analog Intravenous Sept. 25, 2008 Sept. 30, 2021 No Longer Used
61703-0349-09 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-16 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-36 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0350-09 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous Sept. 25, 2014 In Use
61703-0350-10 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous Sept. 25, 2014 In Use
61703-0350-37 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous July 27, 2005 In Use
61703-0350-38 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous July 27, 2005 In Use
61703-0351-59 61703-0351 Methotrexate Sodium Methotrexate Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jan. 29, 2010 Feb. 1, 2010 No Longer Used
61703-0352-07 61703-0352 Methotrexate Sodium Methotrexate Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jan. 29, 2010 Feb. 1, 2010 No Longer Used
61703-0359-59 61703-0359 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 8, 2007 Aug. 31, 2016 No Longer Used
61703-0359-93 61703-0359 Epirubicin Hydrochloride Epirubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 8, 2007 Aug. 31, 2016 No Longer Used
61703-0360-18 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0360-22 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 Oct. 31, 2015 In Use
61703-0360-50 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 25, 2009 Jan. 31, 2016 In Use
61703-0361-35 61703-0361 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 30, 2009 Nov. 21, 2016 No Longer Used
61703-0362-50 61703-0362 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 30, 2009 Nov. 21, 2016 No Longer Used
61703-0363-18 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
61703-0363-22 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
61703-0408-22 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Feb. 26, 2001 Nov. 2, 2011 In Use
61703-0408-25 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Nov. 11, 2013 In Use
61703-0408-41 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Feb. 26, 2001 In Use
61703-0600-05 61703-0600 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61748-0301-01 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-11 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0301-13 61748-0301 Isotretinoin Myorisan 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-01 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-11 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0302-13 61748-0302 Isotretinoin Myorisan 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0303-01 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-11 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0303-13 61748-0303 Isotretinoin Myorisan 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Aug. 26, 2015 In Use
61748-0304-01 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-11 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61748-0304-13 61748-0304 Isotretinoin Myorisan 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 1, 2012 In Use
61755-0008-01 61755-0008 cemiplimab-rwlc LIBTAYO 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Sept. 28, 2018 In Use
61786-0027-57 61786-0027 Methylprednisolone Acetate Depo-Medrol 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intralesional, Intramuscular, Intrasynovial, Soft Tissue Sept. 11, 2014 Sept. 27, 2018 In Use
61786-0049-02 61786-0049 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 29, 2016 Feb. 2, 2017 No Longer Used
61786-0049-03 61786-0049 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 6, 2015 Feb. 2, 2017 No Longer Used

Found 10,000 results in 15 millisecondsExport these results